Manufacturing
Our 77,000-square-foot facility in Indianapolis, Indiana, is state-of-the-art. Purpose-built to be a fully integrated, end-to-end manufacturing center, the facility combines isotope production and drug product manufacturing—a first-of-its-kind model in the United States. With over $160 million invested in this facility to date, the site is currently producing human clinical doses for clinical use and scaling rapidly to produce commercial doses in time. When this site is operating at full capacity, we expect to be able to manufacture over 10,000 doses annually.
Our Indianapolis facility offers on-demand isotope production and drug product manufacturing which will enable distribution within just 2 days of production.
Located in the heart of the Midwest, Indianapolis is a key national distribution hub offering unmatched reach—50% of the U.S. is within a 10-hour drive. This allows for the reliable transfer of doses through road or air transport to destinations across the country and around the world. With multiple major airports within a three-hour radius, we offer fast and reliable worldwide transport directly to patients in need.
Indianapolis is rapidly becoming the epicenter of a thriving radiopharmaceutical ecosystem and is home to the highest concentration of radiopharmaceutical companies in the United States. The State of Indiana is actively strengthening its engagement and support for the radiopharmaceutical industry and has recently submitted a letter of intent with the United States Nuclear Regulatory Commission (NRC) to allow regulatory authority over certain radioactive material by the State of Indiana, which may further streamline the opportunity for RPT development in the state.
